HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy

Frank Alexis, Pamela Basto, Etgar Levy-Nissenbaum, Aleksandar F. Radovic-Moreno, Liangfang Zhang, Eric Pridgen, Andrew Z. Wang, Shawn L. Marein, Katrina Westerhof, Linda K. Molnar, Omid C. Farokhzad

Research output: Contribution to journalArticlepeer-review

140 Scopus citations


(Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen.

Original languageEnglish (US)
Pages (from-to)1839-1843
Number of pages5
Issue number12
StatePublished - Dec 15 2008
Externally publishedYes


  • Affibodies
  • Antitumor agents
  • Nanoparticles
  • PLA-PEG copolymers
  • Targeted therapy

ASJC Scopus subject areas

  • Drug Discovery
  • General Pharmacology, Toxicology and Pharmaceutics
  • Molecular Medicine
  • Biochemistry
  • Pharmacology
  • Organic Chemistry


Dive into the research topics of 'HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy'. Together they form a unique fingerprint.

Cite this